Welcome to our dedicated page for AIxCrypto Holdings SEC filings (Ticker: QLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AIxCrypto Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AIxCrypto Holdings's regulatory disclosures and financial reporting.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) filed a Form 8-K announcing a board-level governance change effective June 20 2025. Independent director Robert B. Lim was appointed Chair of the Audit Committee, succeeding Graydon Bensler, who will remain a committee member. The board affirmed that Lim meets Nasdaq Rule 5605 and SEC Rule 10A-3 independence criteria and is deemed an “audit committee financial expert” under Regulation S-K Item 407(d)(5). The filing states there are no related-party transactions or special arrangements connected to Lim’s elevation. No other management changes, financial results, or transactions were disclosed.